Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
372.32B
Market cap372.32B
Price-Earnings ratio
119.49
Price-Earnings ratio119.49
Dividend yield
2.25%
Dividend yield2.25%
Average volume
10.91M
Average volume10.91M
High today
$153.57
High today$153.57
Low today
$148.04
Low today$148.04
Open price
$148.80
Open price$148.80
Volume
11.17M
Volume11.17M
52 Week high
$156.92
52 Week high$156.92
52 Week low
$77.58
52 Week low$77.58

Stock Snapshot

Merck(MRK) stock is priced at $151.00, giving the company a market capitalization of 372.32B. It carries a P/E multiple of 119.49 and pays a dividend yield of 2.25%.

On 2026-09-23, Merck(MRK) stock moved within a range of $148.04 to $153.57. With shares now at $151.00, the stock is trading +2.0% above its intraday low and -1.7% below the session's peak.

Trading volume for Merck(MRK) stock has reached 11.17M, versus its average volume of 10.91M.

The stock's 52-week range extends from a low of $77.58 to a high of $156.92.

The stock's 52-week range extends from a low of $77.58 to a high of $156.92.

MRK News

Quartz 18h
How the Merck-Moderna mRNA melanoma vaccine is built per patient - qz.com

...

How the Merck-Moderna mRNA melanoma vaccine is built per patient - qz.com
TipRanks 20h
Merck says FDA approves update for U.S. product label for Winrevair

Merck (MRK) announced the U.S. FDA has approved an update to the U.S. product label for Winrevair for injection, 45mg, 60mg, based on the Phase 3 HYPERION trial...

Simply Wall St 20h
Merck Wins Japan Nod For Faster Under Skin Cancer Treatment

Merck (NYSE:MRK) received Japanese approval for KEYTRUDA QLEX, a subcutaneous version of its cancer therapy KEYTRUDA. The new formulation is designed for under...

Merck Wins Japan Nod For Faster Under Skin Cancer Treatment

Analyst ratings

68%

of 31 ratings
Buy
67.7%
Hold
29%
Sell
3.2%

More MRK News

24/7 Wall St. 2d
Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher

Investing Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher A coveted Presidential Symposium slot at E...

Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
Seeking Alpha 2d
Merck secures Japanese approval for subcutaneous Keytruda

Merck (MRK) has secured Japanese regulatory approval for KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous injection, covering all...

Merck secures Japanese approval for subcutaneous Keytruda
TipRanks 2d
Merck says Japan’s MHLW approves Keytruda Qlex

Merck (MRK) announced the Ministry of Health, Labor and Welfare in Japan has approved Keytruda Qlex injection for subcutaneous use for all indications approved...

24/7 Wall St. 4d
Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?

Investing Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story? Both Amgen and Merck write quarterly checks and raise them every year, but onl...

Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?
Benzinga 6d
Moderna Stock Is Surging: What's Going On?

Moderna Inc. (NASDAQ:MRNA) shares are popping Thursday, extending a month-long rally that began with a Phase 3 cancer vaccine breakthrough. Moderna shares are...

Moderna Stock Is Surging: What's Going On?
Simply Wall St 7d
Merck Expands Keytruda Trial Reach, Is 4% Undervalued Enough?

Merck (MRK) just expanded its oncology footprint by agreeing to supply Keytruda for Perspective Therapeutics’ trial that combines targeted alpha therapy [212Pb]...

Merck Expands Keytruda Trial Reach, Is 4% Undervalued Enough?

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.